NM 505
Alternative Names: NM-505; Reformulated metformin - MicroBiome TherapeuticsLatest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator MicroBiome Therapeutics
- Class Antihyperglycaemics; Biguanides; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Gastrointestinal microbiome modulators; Gluconeogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Type-2-diabetes-mellitus in USA (PO)
- 09 Jun 2015 MicroBiome Therapeutics has patent protection for microbiome modulator-metformin combination NM 505 in USA
- 09 Jun 2015 Efficacy and adverse events data from a clinical trial in Type-2 diabetes mellitus presented at the 75th Annual Scientific Sessions of the American Diabetes Association (ADA-2015)